top of page

Topline results from Phase II study of SHP607 in extremely premature infants

Shire’s Phase II study evaluating an investigational protein replacement, SHP607, in extremely premature infants did not meet its primary endpoint of reducing the severity of retinopathy of prematurity (ROP).


source: Shire’s Phase II study evaluating an investigational protein replacement, SHP607, in extremely premature infants did not meet its primary endpoint of reducing the severity of retinopathy of prematurity (ROP).



#Pharmanews

Today's News
Follow us
  • LinkedIn Social Icon
  • Vimeo Social Icon
Newsletter on Pharma Legislation
the newsletter of
bottom of page